Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial - Langdahl, B L; Libanati, C; Crittenden, D B (Lancet, 2017)